7 medtech stories we missed this week: April 14, 2017

[Image from unsplash.com]From FDA approvals to business expansion plans, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. BioTelemetry launches offer to acquire LifeWatch BioTelemetry and LifeWatch announced in an April 9 press release that the 2 companies have entered a transaction agreement that states BioTelemetry will launch a tender offer to acquire all shares of LifeWatch. The LifeWatch shareholders will receive either 10 Swiss francs in cash and 0.1457 shares of BioTelemetry stock per LifeWatch share or 8 Swiss francs in cash and 0.2175 shares of BioTelemetry stock per LifeWatch share. The deal is expected to be worth approximately 260 million Swiss francs. 2. FDA approves marketing of first whole slide imaging system for digital pathology The FDA approved marketing for the Philips IntelliSite Pathology Solution (PIPS), according to an April 12 press release. PIPS is the first whole slide imaging system that allows for review and interpretation of digital surgical pathology slides that are prepared from biopsied tissue. The FDA has not permitted the marketing of a whole slide imaging system for these purposes before. PIPS uses hardware and software to scan and digitize conventional surgical pathology glass slides that have been prepared from biopsied tissue at 400x magnification resolutions. Pathologists can review and interpret those images. 3. Second Sight touts first Asian Argus II implantation Second Sight Medical Products...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Food & Drug Administration (FDA) Regulatory/Compliance Research & Development Acelity BioTelemetry CollPlant LifeWatch MedTech Second Sight Sight Science Toshiba Medical Source Type: news